Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors

@article{Ducharme2012ClinicalEO,
  title={Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors},
  author={F. Ducharme and F. Noya and F. Allen-Ramey and E. Maiese and Joanie Gingras and L. Blais},
  journal={Current Medical Research and Opinion},
  year={2012},
  volume={28},
  pages={111 - 119}
}
OBJECTIVES To examine the real-life effectiveness of inhaled corticosteroids (ICS) versus leukotriene receptor antagonists (LTRA) monotherapy in children with mild or moderate asthma. [...] Key MethodMETHODS Using medical and drug records, we accrued a cohort of 227 children aged 2-17 years, prescribed daily LTRA or ICS monotherapy. LTRA-treated children were matched on age, gender, and previous acute-care visits in a 1:3 ratio to ICS-treated children.Expand
Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids.
  • A. Wu, L. Li, +10 authors T. Lieu
  • Medicine
  • The journal of allergy and clinical immunology. In practice
  • 2014
TLDR
Risks of asthma-related exacerbations did not differ between children who initiated LTRA and ICS, and these findings may be explainable by LTRA, which has similar effectiveness as ICS in real-life usage by residual confounding by indication or other unmeasured factors. Expand
Demographic predictors of leukotriene antagonist monotherapy among children with persistent asthma.
TLDR
Children 5- to 13-years of age, rural children, and Caucasian children were more likely to receive LTRAM, and uncovering provider rationale and practices as well as patient influences on this prescribing pattern may be helpful in optimizing asthma controller therapy. Expand
High inhaled corticosteroids adherence in childhood asthma: the role of medication beliefs
TLDR
Most patients with mild persistent asthma do not use maintenance inhaled corticosteroids and most individuals remain poorly controlled; even in settings where patients have free access to medications, adherence remains suboptimal; many discontinue asthma controllers when asymptomatic and restart therapy when deemed required. Expand
Comparative effectiveness of budesonide inhalation suspension and montelukast in children with mild asthma in Korea
  • Jina Shin, Seun Oh, +6 authors S. Hong
  • Medicine
  • The Journal of asthma : official journal of the Association for the Care of Asthma
  • 2019
TLDR
Montelukast patients had better adherence, a longer time to loss of persistency, and were less likely to experience an exacerbation-related office visit in the post-index period than BIS patients. Expand
Weight status and nonadherence to asthma maintenance therapy among children enrolled in a public drug insurance plan
TLDR
It is suggested that nonadherence may be a potential contributor to higher morbidity in children with obese-asthma, and excess weight status is a possible determinant of primaryNonadherence in children initiating low-dose ICS and secondarynonadherence to higher- dose ICS regimens. Expand
Cessation of long-acting β2-agonist in children with persistent asthma on inhaled corticosteroids
TLDR
Most asthmatic children can be successfully weaned off long-acting β2-agonists to inhaled corticosteroid monotherapy, and the beneficial effects of ICS/LABA in children are limited to improving lung function and short-actingβ2-agonist use. Expand
Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma
TLDR
Systemic corticosteroids, but not inhaled corticosterone, were significantly associated with increased odds of fracture in the pediatric asthma population, compared with no use and other medication use. Expand
Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study.
TLDR
ICS+LABA therapy seems to be more effective than ICS+LTRA therapy in the management of asthma, regardless of adherence. Expand
Montelukast for the high impact of asthma exacerbations in Venezuela: a practical and valid approach for Latin America?
TLDR
This real-life pilot study shows that a simplified strategy with oral Montelukast was practical and effective in controlling exacerbations in an asthmatic population of a vulnerable community from Caracas, and reinforces the role of primary care in asthma treatment. Expand
Montelukast use over the past 20 years: monitoring of its effects and safety issues
TLDR
It is identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Inhaled corticosteroids vs. leukotriene-receptor antagonists and asthma exacerbations in children.
TLDR
ICS appears to be more frequently prescribed as an intermittent than a daily controller therapy resulting in less use, which may contribute to the apparent lower effectiveness compared to LTRA. Expand
Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma.
TLDR
The more favorable clinical, pulmonary, and inflammatory responses to an ICS than to an LTRA provide pediatric-based group evidence to support ICSs as the preferred first-line therapy for mild-to-moderate persistent asthma in children. Expand
Adherence to Prescribed Treatment for Asthma: Evidence from Pharmacy Benefits Data
TLDR
In clinical practice settings, patients initiating LTRA monotherapy have about twice the adherence as patients initiating ICS or ILBA monotherapy, which is important to consider in the prescription of oral vs. inhaled asthma medications. Expand
Treatment Persistence with Leukotriene Receptor Antagonists and Inhaled Corticosteroids
TLDR
The findings of this observational study indicate a far from optimal persistence to LTRAs and ICSs in asthmatic patients, which might result in better effectiveness. Expand
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
TLDR
For most asthma outcomes, ICS at 400 mcg/day of beclomethasone-equivalent are more effective than anti-leukotriene agents given in the usual licensed doses, and for nocturnal awakenings, rescue medication use, and quality of life. Expand
"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma.
  • D. Bukstein, A. Luskin, A. Bernstein
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2003
TLDR
The results suggest that oral montelukast and inhaled fluticasone have similar real-world efficacies in the treatment of children with mild asthma, possibly as a result of the significantly better adherence with oral montelsukast therapy compared with inhaled Fluticas one. Expand
Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone*
TLDR
Subgroup analyses suggest a differential effect of age on the relationship between treatment and asthma-related resource use, with children 2–5 years observed to have less resource use while on montelukast. Expand
Seasonal Patterns of Controller and Rescue Medication Dispensed in Underserved Children with Asthma
TLDR
Timing of asthma monitoring visits to occur before peak prescription fill months, i.e., August and December for an asthma “tune-up,” theoretically could improve asthma control and benefit children with persistent asthma. Expand
Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The Mosaic Study
TLDR
The first direct comparison between montelukast and an ICS measuring differences in multiple parameters of asthma control in children with mild persistent asthma establishes the noninferiority of montelUKast compared with fluticasone in terms of RFDs; however, in termsof FEV1, systemic corticosteroid use, number of asthma attacks and β-agonist use, flutic asone was significantly superior to montelucast. Expand
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
TLDR
The safety and efficacy of anti-leukotrienes compared to inhaled corticosteroids as monotherapy in adults and children with asthma is determined and better insight into the influence of patient and treatment characteristics on the magnitude of effects is provided. Expand
...
1
2
3
4
5
...